Research on early-stage Indian consumer companies — who is building them, who is funding them, and which of the two the market is mispricing.
Naturis Cosmetics took its first institutional cheque this week — ₹33.7 Cr from the Marico promoter family's investment office. You have never heard of Naturis. You have used it. It manufactures for Nykaa, Plum, Pilgrim, Purplle, Bare Anatomy and Ustraa, and its round says more about where margin sits in Indian beauty than any brand round this year.
The coverage of Foxtale's KOSÉ-led Series C is about category expansion. The careers page says something else: a brand built on a repeat-rich website is quietly staffing a field force. Read the hiring page as a forward indicator and the round stops looking like a revenue round.
Lotus Herbals put ₹10 crore into KorinMi and took a board seat. The market is reading it as a beauty brand investment. It is an investment in a clinic-led service layer, where diagnosis comes first and the product is the annuity sitting on top of a trust event the customer has already paid for — a different asset, priced as though it were the same one.
Romi finished its Sephora Hong Kong rollout with zero external capital. KOMFYMED took the Watsons derma slot that has belonged to La Roche-Posay and Avène. Dr. Sheth's put the BIS in-vivo line ahead of the marketing claim in its SKU title. In each case the retailer or the regulator recognised durability that already existed rather than creating it.
Most weeks I spend an hour reading salon-owner LinkedIn out of Lucknow, Indore and Coimbatore. The shelf photos with no brand tag are the ones I save. This is the signal map I use to find Indian personal care brands before they raise — where it has worked, where it has failed, and the dated call it produces.
Bakingo crossed ₹300 Cr in FY25 on a ₹16.5 Cr loss and raised ₹100 Cr from Faering at a ₹1,643 Cr mark. The visible growth engine is kitchen count. But a cake is bought for an occasion, and the number of occasions in a household per year is fixed. An operating memo on why I would not spend this round on the 31st city.
A brand-building fund underwrote equipment at the first cheque. In home care the competitor is HUL and Reckitt, there is no premium narrative to hide behind, and gross margin is the entire strategy — which makes this a cost-structure bet wearing a brand bet's clothes.
Purplle, GIVA, Jar, Niyo, Leverage Edu, Dezy, Agilitas. Ask what sector connects them and you cannot answer. Ask what they have in common as purchase decisions and the mandate becomes obvious: Spring underwrites commoditised categories where brand is the only available moat — which is exactly where a fund of ex-CMOs is worth more than its capital.
Bold Care, Perfora, Asaya, Blue Tokai, GreenGrahi. Read them as sectors and they scatter. Read them as consumer beliefs and one pattern holds: every one is a category with a wrong default, where the first mover pays for the education and the second mover free-rides on it.
At seed, the best deal flow comes from founders you have already backed. Reputation among founders is not a soft asset; it is the pipeline. Almost no fund measures it. Kae Capital does, and publishes the number — which is more interesting than the number itself.
Consumer AI in India is still being written about as an app category. That framing is already outdated. AI is becoming the layer that shapes the shortlist before a consumer reaches a brand — which makes it a distribution shift, not a product shift, and changes what a seed fund should be underwriting.
Banza raised $1M from Campus Fund and was covered as consumer AI. Read the cap table, the CBO's history and the Play Store listing instead of the funding press, and it is a zero-knowledge identity stack that changed its language when Web3 fundraising dried up. Three things the coverage missed.